AlphaValue raises target for Sartorius Stedim stock to EUR 253

Published on 10/14/2026 at 11:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

AlphaValue cut 2026 earnings per share by 9.20 percent. Sartorius Stedim stock is 4.27 percent below its EUR 225.00 high on October 14, 2026.

Target revision and operating backdrop

AlphaValue lifted its Sartorius Stedim target to EUR 253 on October 9, 2026.
First-half 2026 revenue reached EUR 1.527 billion, with an EBITDA margin of 31.40 percent.
Sartorius Stedim stock trades at EUR 215.40 at 11:33 a.m. CEST at Lang & Schwarz on October 14, 2026.
The company is scheduled to present nine-month 2026 results on October 22, 2026.

Isometrische Prozessdarstellung einer Bioprozess-Wertschöpfungskette von Zellkultur bis Abfüllung — Sartorius Stedim Biotech isometrisches 3D-Diagramm der Bioprozess-Wertschöpfungskette von Zellkultur bis Abfüllung, ISIN FR0013154002, Illustration mit AI erstellt.

Sartorius Stedim Biotech (FR0013154002) is trading at EUR 215.40 at Lang & Schwarz on October 14, 2026, at 11:33 a.m. CEST. Finimize reported on October 9, 2026, that AlphaValue/Baader Europe raised its price target to EUR 253 while cutting its 2026 and 2027 earnings-per-share forecasts.

Three milestones shape the story

On July 22, 2026, Sartorius Stedim reported first-half revenue of EUR 1.527 billion and an EBITDA margin of 31.40 percent, according to the company investor-relations page. On October 6, 2026, the stock reached EUR 219.60 during a session that highlighted the EUR 217.20 resistance level, as reported by Ideal Investisseur. On October 9, 2026, AlphaValue/Baader Europe raised its target to EUR 253, the latest quantified analyst event.

What does the target imply?

The target revision is notable because AlphaValue also cut its 2026 earnings-per-share forecast by 9.20 percent and its 2027 forecast by 7.96 percent, to EUR 4.69 and EUR 5.72. The analysis links the higher target to discounted-cash-flow and net-asset-value assumptions, while pointing to operating leverage, consumables and deleveraging as longer-term supports. That combination shifts the debate from near-term earnings optics toward cash generation.

Next date is October 22

The next scheduled company event is the nine-month 2026 results conference on October 22, 2026, at 1 p.m. CEST, according to the Sartorius Stedim Biotech investor-relations page. finanzen.ch reported on October 7, 2026, that analysts expected third-quarter revenue of EUR 755.6 million, up 7.07 percent from EUR 705.7 million a year earlier.

Valuation stays tied to execution

Sartorius Stedim is valued at EUR 20.9 billion as of October 14, 2026, while the 52-week range is EUR 150.00 to EUR 225.00. The current price is 4.27 percent below that high, leaving the October 22 results as the next test of whether the forecast recovery is translating into reported growth. The company specializes in bioprocess equipment, consumables and services for the biopharmaceutical industry and is listed on Euronext Paris under ticker DIM.

The further course of trading is shown by the continuously updated real-time quote of Sartorius Stedim stock.